Cargando…

SFRP4 drives invasion in gastric cancer and is an early predictor of recurrence

OBJECTIVE: Gastric cancer patients generally have a poor outcome, particularly those with advanced-stage disease which is defined by the increased invasion of cancer locally and is associated with higher metastatic potential. This study aimed to identify genes that were functional in the most fundam...

Descripción completa

Detalles Bibliográficos
Autores principales: Busuttil, Rita A., George, Joshy, House, Colin M., Lade, Stephen, Mitchell, Catherine, Di Costanzo, Natasha S., Pattison, Sharon, Huang, Yu-Kuan, Tan, Patrick, Cheong, Jae-Ho, Rha, Sun Young, Boussioutas, Alex
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Singapore 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8064978/
https://www.ncbi.nlm.nih.gov/pubmed/33277667
http://dx.doi.org/10.1007/s10120-020-01143-8
Descripción
Sumario:OBJECTIVE: Gastric cancer patients generally have a poor outcome, particularly those with advanced-stage disease which is defined by the increased invasion of cancer locally and is associated with higher metastatic potential. This study aimed to identify genes that were functional in the most fundamental hallmark of cancer, namely invasion. We then wanted to assess their value as biomarkers of gastric cancer progression and recurrence. DESIGN: Data from a cohort of patients profiled on cDNA expression arrays was interrogated using K-means analysis. This genomic approach classified the data based on patterns of gene expression allowing the identification of the genes most correlated with the invasion of GC. We evaluated the functional role of a key protein from this analysis in invasion and as a biomarker of recurrence after curative resection. RESULTS: Expression of secreted frizzled-related protein 4 (SFRP4) was identified as directly proportional to gastric cancer invasion. This finding was validated in multiple, independent datasets and its functional role in invasion was also confirmed using invasion assays. A change in serum levels of SFRP4 after curative resection, when coupled with AJCC stage, can accurately predict the risk of disease recurrence after curative therapy in an assay we termed PredictR. CONCLUSIONS: This simple ELISA-based assay can help predict recurrence of disease after curative gastric cancer surgery irrespective of adjuvant therapy. The results require further evaluation in a prospective trial but would help in the rational prescription of cancer therapies and surveillance to prevent under or over treatment of patients after curative resection. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s10120-020-01143-8.